New report shows influence of weight loss medication on shopping habits

A new report reveals how the increasing use of GLP-1 weight loss medications is reshaping consumer behavior, with notable impacts on shopping patterns, dietary choices, and lifestyle adjustments. According to a study conducted by EY, one of the world’s leading professional services firms, the widespread adoption of these drugs, commonly known as weight loss injections, is altering the way Australians approach groceries, dining, and personal care. The report highlights that GLP-1 medications work by mimicking a hormone called glucagon-like peptide-1, which helps regulate appetite and modify food preferences. As a result, users are experiencing shifts in their eating habits, including reduced cravings for salty and sweet foods, increased preference for protein-rich items, and a general shift toward healthier diets. These changes are not limited to individuals using the medication; they are beginning to influence broader consumer trends, especially among health-conscious groups. Lisa Nijssen-Smith, one of the report’s lead authors, noted that approximately 10 percent of the Australian adult population is currently using GLP-1 drugs, and projections suggest this figure could rise to 30 percent within the next ten years. This growing trend is having a measurable effect on supermarket purchases. Data collected by the researchers show a noticeable decrease in the purchase of processed snacks and an increase in the selection of fresh produce, lean proteins, and whole foods. While overall spending levels remain relatively stable, consumers are becoming more discerning about what they buy, opting for smaller portions and higher-quality ingredients. Beyond the grocery store, the impact of GLP-1 usage extends to other areas of daily life. The report indicates that many users are reducing their frequency of dining out, with nearly half—44 percent, reporting they eat outside less frequently than before starting the medication. When they do dine out, they tend to prioritize quality over quantity, choosing restaurants that offer healthier menu options. This shift poses challenges for the hospitality industry, which must adapt its offerings to meet the evolving expectations of diners. Additionally, users of GLP-1 medications are showing interest in personal grooming and skincare. The report notes that many individuals are investing more time and money into maintaining a better appearance, reflecting a broader cultural emphasis on self-care and health. This includes frequent wardrobe updates and increased spending on beauty products, suggesting that the influence of the medication is not confined to diet alone. The findings from Australia are drawing attention from businesses in neighboring regions, including New Zealand. Nijssen-Smith pointed out that while local markets have unique infrastructures and policies, the trends observed in Australia mirror those seen in the United States several years earlier. She believes these insights can serve as a valuable guide for New Zealand companies looking to adjust their strategies in response to changing consumer behaviors. As the use of GLP-1 medications continues to grow, the implications for retail, food service, and personal care industries are likely to become even more pronounced. Businesses that can effectively anticipate and respond to these shifts may gain a competitive edge in the evolving marketplace.